Petros Pharmaceuticals Inc Stock Price, News & Analysis

Petros Pharmaceuticals (Nasdaq: PTPI) has successfully closed a registered direct offering and private placement, raising approximately $7.5 million. The funds will support the expansion of its men's health platform and provide working capital. This capital boost marks the company's strongest cash position to date, enhancing their strategic plans in the men's health category. Katalyst Securities LLC acted as the financial advisor for this transaction. Petros aims to lead the market by developing innovative therapeutics for issues such as erectile dysfunction and Peyronie's disease.

Petros Pharmaceuticals, a leader in men's health therapeutics, has announced a definitive agreement for the sale of 2,186,589 shares at $3.43 per share, aiming to raise approximately $7.5 million. This includes a registered direct offering and a private placement. The proceeds will support the expansion of its men's health platform and general corporate purposes. The offering is expected to close around December 27, 2021. Unregistered shares and warrants were also included, with the company agreeing to register them within 15 days.

Petros Pharmaceuticals (Nasdaq: PTPI) reported positive results from its over-the-counter (OTC) draft label comprehension study for STENDRA® (avanafil), an erectile dysfunction drug. Conducted with 453 participants, including those with low health literacy, the study assessed understanding of key label messages. The favorable results support Petros's plans to seek FDA approval for OTC access to STENDRA, potentially the first of its kind in the U.S. This step aims to enhance accessibility for the estimated 30 million men suffering from erectile dysfunction, of which only about 25% currently receive therapy.

Petros Pharmaceuticals (Nasdaq: PTPI) has successfully closed a registered direct offering and private placement, raising approximately $10 million from its largest investor and other existing investors. The company will use the funds to expand its men's health platform, working capital, and general corporate purposes. CEO Fady Boctor stated that this additional funding strengthens their position as they aim to enhance the availability of STENDRA and grow their men's health portfolio. The firm is focused on being a leading provider of therapeutics for men's health issues.

Petros Pharmaceuticals, a leader in men's health therapeutics, will be presenting at the Benzinga Global Small Cap Conference on December 8, 2021. President and Chief Commercial Officer Fady Boctor is scheduled to deliver his presentation at 1:35 PM ET. Additionally, Mr. Boctor will be available for one-on-one meetings throughout the event, which runs from December 8 to 9. Petros focuses on addressing men's health issues, including erectile dysfunction and hormone health, by developing innovative therapeutic solutions.

Petros Pharmaceuticals (Nasdaq: PTPI) announced a definitive agreement to sell 3,333,333 shares of common stock at $3.00 per share, generating approximately $10 million in gross proceeds. The offering includes a registered direct offering of 2,153,333 shares and a private placement of 1,180,000 shares. Additionally, the company will issue warrants for 2,500,000 shares at an exercise price of $3.50. The funds will support the expansion of its men's health platform and general corporate purposes, with the transaction expected to close by December 2, 2021.

Petros Pharmaceuticals (Nasdaq: PTPI) reported Q3 2021 results, revealing net sales of $2.2 million, down from $3.5 million in Q3 2020. Despite record-level STENDRA® prescriptions and a 46% increase in gross sales from the Prescription Medicines segment, net sales were negatively impacted by higher allowances, including product returns and discounts. Operating expenses rose to $3.6 million, leading to an adjusted EBITDA loss of ($1.9 million). Cash reserves decreased to $8.1 million as of September 30, 2021, down from $17.1 million at year-end 2020.

Petros Pharmaceuticals (Nasdaq: PTPI) will present a corporate overview at the Q4 Investor Summit Conference, held virtually on November 16-17, 2021. President and Chief Commercial Officer Fady Boctor is scheduled to deliver the presentation on November 17 at 1:15 PM ET. He will also be available for one-on-one meetings during the event. Petros aims to be a leader in specialized men’s health therapeutics, focusing on issues such as erectile dysfunction and hormonal health.

Petros Pharmaceuticals (Nasdaq: PTPI) announced an expansion of its program for H100, a non-invasive topical treatment for Peyronie's disease. H100 is designed to alleviate the inflammatory issues causing pain and irregularities in penile shape. Through an exclusive agreement with Hybrid Medical LLC, Petros aims to position H100 as the first approved non-invasive treatment for this condition. The company expresses optimism about H100's potential safety profile and expedited development timeline under a 505(b)(2) submission process.